RECENT ADVANCES IN HPLC METHOD DEVELOPMENT AND VALIDATION FOR THE ESTIMATION OF ANTI HYPERTENSIVE DRUGS: A REVIEW

P. Sri Jyothi*, Vasala Mounika, Arunabha Mallik

ABSTRACT

Hypertension remains one of the leading global cardiovascular disorders, requiring long
term pharmacotherapy
using diverse classes of anti hypertensive drugs such as ACE inhibitors, ARBs, β blockers, calcium c hannel
blockers, diuretics, and vasodilators. The increasing demand for high quality pharmaceutical products, the rise of
fixed dose combinations (FDCs), and the need for stability indicating assays have intensified the development of
highly selective, rob ust, and validated HPLC analytical methods. Recent years have witnessed significant
advancements in HPLC technologies, including the introduction of core shell columns, monolithic supports,
UHPLC, AQbD driven method development, and green analytical chemis try (GAC) principles. This review
provides a comprehensive analysis of the latest developments in HPLC method design, optimization, and validation
for the quantitative estimation of antihypertensive drugs in bulk and dosage forms. Detailed tables summarize
chromatographic conditions, mobile phases, validation parameters, and system suitability criteria from numerous
published works. The review also discusses emerging challenges, method greening, risk assessment, regulatory
requirements, and future perspecti ves.

Keywords: HPLC, Antihypertensive drugs, Method development, Validation, Stability indicating assay, AQbD, Green analytical chemistry.